European guidelines for quality assurance in cervical histopathology

Acta Oncologica

Volumn 50, Issue 5, 2011, Pages 611-620

  Bulten, Johan ^a   Horvat, Reinard ^b   Jordan, Joe ^c   Herbert, Amanda ^d   Wiener, Helene ^b   Arbyn, Marc ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY TECHNIQUE; CANCER STAGING; COLPOSCOPY; CORRELATION ANALYSIS; CURETTAGE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENDOCERVICAL CURETTAGE; EXCISION; FEMALE GENITAL TRACT CYTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUNCH BIOPSY; QUALITY CONTROL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; WART VIRUS;

CERVIX UTERI; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; EUROPE; FEMALE; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE; VAGINAL SMEARS;

EID: 79956073479     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.555779     Document Type: Review

References (44)

1. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: Recommendations for collecting samples for conventional and liquid- based cytology. Cytopathology 2007;18:133-9. (Pubitemid 46934510)
2. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer PJ, Arbyn M. European guidelines for quality assurance in cervical cancer screening: Recommendations for cervical cytology terminology. Cytopathology 2007;18:213-9. (Pubitemid 47076369)
3. Giordano L, Webster P, Szarewski A, et al. Improving the quality of communication in organised cervical cancer screening. Patient Educ Couns 2008;72:130-6. (Pubitemid 351763872)
4. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: An appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol 2007;38:189-97. (Pubitemid 46275523)
5. Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: Recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008;19:342-54.
6. Jordan J, Martin-Hirsch P, Arbyn M, et al. European guidelines for management of abnormal cervical cytology, Part 2. Cytopathology 2009;20:5-16.
7. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second Edition-Summary document. Ann Oncol 2010;21:448-58.
8. Costa MJ, Grimes C, Tackett E, Naib ZM. Cervicovaginal cytology in an indigent population. Comparison of results for 1964, 1981 and 1989. Acta Cytol 1991;35:51-6.
9. Singer A, Monaghan JM. Lower genital tract precancer: Colposcopy, pathology and treatment. 2nd ed. Oxford: Blackwell Science Ltd.; 2000.
10. European Commission. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008.
11. Jordan J, Martin-Hirsch P, Arbyn M, et al. Chapter 6: Management of abnormal cervical cytology. In: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al., editors. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg, Office for Official Publications of the European Communities; 2008. p. 191-232.
12. Obermair A, Wanner C, Bilgi S, et al. The infl uence of vascular space involvement on the prognosis of patients with stage IB cervical carcinoma: Correlation of results from hematoxylin and eosin staining with results from immunostaining for factor VIII-related antigen. Cancer 1998;82:689-96. (Pubitemid 28090280)
13. Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic infl uence of blood and lymphatic vessel invasion in earlystage cervical cancer. Clin Cancer Res 2001;7:93-7. (Pubitemid 32110210)
14. IARC. Cervix cancer screening. IARC handbooks of cancer prevention. Vol. 10. Lyon: IARC Press; 2005.
15. WHO. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
16. Mitchell MF, Tortolero-Luna G, Wright TC, et al. Cervical human apillomavirus infection and intraepithelial neoplasia: A review. J Natl Cancer Inst Monogr 1996;17-25.
17. Ostor AG, Mulvany N. The pathology of cervical neoplasia. Curr Opin Obstet Gynecol 1996;8:69-73. (Pubitemid 26112548)
18. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 1998;92:727-35. (Pubitemid 28440819)
19. Herbert A, Arbyn M, Bergeron C. Why CIN3 and CIN2 should be distinguished on histological reports. Cytopathology 2008;19:63-4.
20. Ismail SM, Colclough AB, Dinnen JS, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ 1989;298:707-10. (Pubitemid 19084499)
21. Stoler MH, Schiffman MA. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA 2001;285:1500-5.
22. Crum CP, Egawa K, Fu YS, et al. Atypical immature metaplasia (AIM). A subset of human papilloma virus infection of the cervix. Cancer 1983;51:2214-9. (Pubitemid 13106846)
23. Klaes R, Benner A, Friedrich T, et al. p16INK4A immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99. (Pubitemid 35239415)
24. NHSCSP. Histopathology reporting in cervical screening. Working party of the Royal College of Pahtologists and the NHS Cervical Screening Programme. Shefield: NHS Cancer Screening Programmes; 1999. Report No.: 10.
25. Goldstein NS, Ahmad E, Hussain M, Hankin RC, Perez- Reyes N. Endocervical glandular atypia: Does a preneoplastic lesion of adenocarcinoma in situ exist? Am J Clin Pathol 1998;110:200-9. (Pubitemid 28357659)
26. Horn LC, Riethdorf L, Loning T. Leitfaden fü r die Prä p-aration uteriner Operationspr ä prate. Pathologe 1999;20: 9-14. (Pubitemid 29148557)
27. Robboy SJ, Kraus FT, Kurman RJ. Gross discription: Processing and reporting of gynecologic and obstretric specimens. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th ed. Springer-Verlag; 1994. p. 1225-40.
28. Robboy SJ, Russell P, Anderson MC, Bentley RC. Cutup-the gross description, processsing and reporting of specimens. Pathol Female Reproduct Tract 2002;861-77.
29. Heatley MK. How many histological levels should be examined from tissue blocks originating in cone biopsy and large loop excision of the transformation zone specimens of cervix? J Clin Pathol 2001;54:650-1. (Pubitemid 32756452)
30. Breitenecker G, Wiener H, Stani J. Cervical cancer screening in Austria. Eur J Cancer 2000;36:2189-90.
31. Kobak WH, Roman LD, Felix JC, Muderspach LI, Schlaerth JB, Morrow CP. The role of endocervical curettage at cervical conization for high-grade dysplasia. Obstet Gynecol 1995;85:197-201.
32. Hoffman MS, Sterghos SJr, Gordy LW, Gunasekar D. Evaluation of the cervical canal with the endocervical brush. Obstet Gynecol 1993;82:573-577. (Pubitemid 23278261)
33. Mogensen ST, Bak M, Dueholm M, et al. Cytobrush and endocervical curettage in the diagnosis of dysplasia and malignancy of the uterine cervix. Acta Obstet Gynecol Scand 1997;76:69-73. (Pubitemid 27050975)
34. Boardman LA, Meinz H, Steinhoff MM, Heber WW, Blume J. A randomized trial of the sleeved cytobrush and the endocervical curette. Obstet Gynecol 2003;101:426-30. (Pubitemid 36288479)
35. Pretorius RG, Zhang WH, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004;191:430-4. (Pubitemid 39178694)
36. Bulten J, van der Laak JA, Gemmink JH, Pahlplatz MM, de Wilde PC, Hanselaar AG. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 1996;178:268-73.
37. Bulten J, de Wilde PC, Schijf C, et al. Decreased expression of Ki-67 in atrophic cervical epithelium of post-menopausal women. J Pathol 2000;190:545-53. (Pubitemid 30164484)
38. Smela M, Chosia M, Domagala W. Proliferation cell nuclear antigen (PCNA) expression in cervical intraepithelial neoplasia (CIN). An immunohistochemical study. Pol J Pathol 1996;47:171-4. (Pubitemid 27095196)
39. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92: 276-84. (Pubitemid 32225381)
40. Anttila A, Ronco G, Lynge E, et al. Chapter 2: Epidemiological guidelines for quality assurance in cervical cancer screening. In: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al., editors. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg, Office for Official Publications of the European Communities; 2008. p. 11-52.
41. Ronco G, Anttila A. Chapter 7: Summary table of key performance indicators. In: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al., editors. European guidelines for quality assurance in cervical cancer screening, 2nd edition. Luxembourg, Office for Official Publications of the European Communities; 2008. p. 231-42.
42. Vutuc C, Haidinger G, Waldhoer T, Ahmad F, Breitenecker G. Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria. Wien Klin Wochenschr 1999;111:354-9. (Pubitemid 29232600)
43. Wiener HG, Klinkhamer P, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: Recommendations for cytology laboratories. Cytopathology 2007;18:67-78. (Pubitemid 46496716)
44. FIGO. FIGO annual report on the results of treatment in gynaecological cancer. 24th volume. J Epidemiol Biostat 2000;Special issue:x.